All In MedTech

Device Trial Radar · NCT06096428

Hemolysis During Pulsed-field and Radiofrequency Ablation

The Assessment of Intravascular Peri-procedural Hemolysis During Catheter Ablation for Atrial Fibrillation Using Radiofrequency and Pulsed-field Energy

Last checked: Nov 20, 2026Latest source record: Nov 15, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Nov 15, 2023

Primary completion

Mar 30, 2024

Study completion Mar 30, 2024

Sponsor

Lead sponsor
Charles University, Czech RepublicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Oct 23, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
No
Who can join
All sexes, from 18 years, up to 75 years

Summary

As written by the sponsor on the registry.

Hemolysis during and after catheter ablation will be compared between catheter ablation performed using radiofrequency and pulsed-field energy. Consecutive patients indicated for catheter ablation for AF will be enrolled, catheter ablation will be done using standard catheters (Qdot, Biosense Webster for RF, and Farapulse, Boston-Scientific for PF). Blood samples will be drawn at the beginning of ablation (T1), at the end of ablation (T2), and one day after the procedure (T3). Hemolysis will be analyzed using flow cytometry, ELISA and standard biochemistry and compared between RF and PF patients, Primary hypothesis is that hemolysis level will be higher after PF ablation compared to RF ablation.

Conditions

  • Atrial Fibrillation
  • Hemolysis
  • Pulsed-field Ablation

Interventions

  • Pulsed-field ablationDevice

    Pulsed-field ablation will be done using pentaspline catheter (Farawave, Boston Scientific) and pulsed-field energy generator. The goal will be achieve of electrical isolation of pulmonary veins.

  • Radiofrequency ablationDevice

    Pulmonary vein isolation will be done using radiofrequency catheter (Qdot, Biosense-Webster) and generator of radiofrequency energy (nGEN, Biosense-Webster).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Erythrocyte (red blood cells, RBC) microparticlesTime frame: One day after the procedure
  2. Cell free hemoglobinTime frame: One day after the procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Cardiocenter, 3rd Medical School, Charles University and University Hospital Kralovske Vinohrady

    Prague, Czechia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.